For-Profit or Non-Profit? That is the ($100-Billion) Question. At the 7 July PSYCH Investor Summit: Research & Development, MAPS’ founder Rick Doblin and atai Life Sciences founder Christian Angermayer engaged in a one-on-one discussion on the intersection of for-profit and nonprofit psychedelic organisations. Doblin and Angermayer discuss the merit of psychedelic legalisation, access to capital and collaborative opportunities today’s increasingly competitive business landscape.

About Rick Doblin, Ph.D., Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS):

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.

About Christian Angermayer, Founder, atai Life Sciences:

Christian Angermayer is an entrepreneur, investor and film enthusiast. He is the founder of Apeiron Investment Group, his family office and merchant banking business. Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate. Apeiron completes deals across the entire lifecycle and balance sheet of a company, from non-listed Seed/Start Up investments to larger scale Restructuring and Special Situations deals (mostly listed).
With his biotech company atai Life Sciences, Christian has the ambitious goal to enable people to live healthier and happier lives. atai’s focus is on developing solutions for the more than 300 million people who suffer from depression, especially by bringing back formerly vilified drugs like psychedelics into the legal realm.

About PSYCH:

PSYCH is a premium business-to-business media and content platform for the psychedelic science and healthcare industry.

The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace.

We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.

To learn more about us, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or view our insight-rich Psychedelics as Medicine Report:

Web: [ Ссылка ]
Twitter: [ Ссылка ]_
LinkedIn: [ Ссылка ]

свернуть